Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

On March 1, 2021, Selecta Biosciences (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., and CFO Brad Dahms will participate in the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. EST on March 9. Selecta is known for its ImmTOR™ platform, which aims to develop therapies that address unwanted immune responses. Their upcoming clinical trial focuses on treatments for methylmalonic acidemia in collaboration with AskBio.

WATERTOWN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., and Chief Financial Officer, Brad Dahms, will participate in the virtual H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Tuesday, March 9, 2021.

A webcast will also be available in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com

FAQ

What is the date of the H.C. Wainwright Global Life Sciences Conference for Selecta Biosciences (SELB)?

The conference will be held on March 9-10, 2021.

Who will represent Selecta Biosciences at the H.C. Wainwright Conference?

CEO Carsten Brunn, Ph.D., and CFO Brad Dahms will represent the company.

When will Selecta Biosciences' presentation be available for viewing?

The presentation will be available on-demand starting at 7 a.m. EST on March 9, 2021.

What is Selecta Biosciences' ImmTOR™ platform?

ImmTOR™ is a platform developed by Selecta to create therapies that mitigate unwanted immune responses.

What clinical trials are Selecta Biosciences (SELB) planning to initiate?

They are expected to begin trials targeting methylmalonic acidemia in early 2021.

What product candidate did Selecta recently license for chronic refractory gout?

Selecta licensed its Phase 3 product candidate, SEL-212, to Sobi.